Dynamic change of CD8 T cell: immunotherapy fate tell?
作者信息
Brueckl Wolfgang M
机构信息
Department of Respiratory Medicine, Allergology and Sleep Medicine, Paracelsus Medical University, General Hospital Nuernberg, Nuremberg, Germany.
出版信息
Transl Lung Cancer Res. 2023 May 31;12(5):944-947. doi: 10.21037/tlcr-23-139. Epub 2023 May 10.
Abstract
摘要
相似文献
1
Dynamic change of CD8 T cell: immunotherapy fate tell?
Transl Lung Cancer Res. 2023 May 31;12(5):944-947. doi: 10.21037/tlcr-23-139. Epub 2023 May 10.
2
Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.
BMC Pulm Med. 2022 Apr 28;22(1):166. doi: 10.1186/s12890-022-01951-x.
3
TCR Repertoire Diversity of Peripheral PD-1CD8 T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non-Small Cell Lung Cancer.
Cancer Immunol Res. 2020 Jan;8(1):146-154. doi: 10.1158/2326-6066.CIR-19-0398. Epub 2019 Nov 12.
4
Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment.
J Immunother Cancer. 2023 Feb;11(2). doi: 10.1136/jitc-2022-005509.
5
Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma.
Front Oncol. 2021 Jun 4;11:658690. doi: 10.3389/fonc.2021.658690. eCollection 2021.
6
Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
J Thorac Oncol. 2018 Apr;13(4):521-532. doi: 10.1016/j.jtho.2017.11.132. Epub 2017 Dec 18.
7
Potential predictive value of change in inflammatory cytokines levels subsequent to initiation of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer.
Cytokine. 2021 Feb;138:155363. doi: 10.1016/j.cyto.2020.155363. Epub 2020 Nov 29.
8
Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: A multiplex immunohistochemistry-based single-cell analysis.
Lung Cancer. 2022 Dec;174:71-82. doi: 10.1016/j.lungcan.2022.10.012. Epub 2022 Oct 30.
9
Peripheral blood lymphocytes differentiation patterns in responses / outcomes to immune checkpoint blockade therapies in non-small cell lung cancer: a retrospective study.
BMC Cancer. 2023 Jan 25;23(1):83. doi: 10.1186/s12885-023-10502-4.
10
Integration of tumor extrinsic and intrinsic features associates with immunotherapy response in non-small cell lung cancer.
Nat Commun. 2022 Jul 13;13(1):4053. doi: 10.1038/s41467-022-31769-4.
本文引用的文献
1
Immune profile analysis of peripheral blood and tumors of lung cancer patients treated with immune checkpoint inhibitors.
Transl Lung Cancer Res. 2022 Nov;11(11):2192-2207. doi: 10.21037/tlcr-22-421.
2
Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy.
Cancer Immunol Res. 2023 Feb 3;11(2):164-170. doi: 10.1158/2326-6066.CIR-22-0524.
3
Advanced non-small-cell lung cancer: how to manage non-oncogene disease.
Drugs Context. 2022 Jul 8;11. doi: 10.7573/dic.2022-2-4. eCollection 2022.
4
Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.
BMC Pulm Med. 2022 Apr 28;22(1):166. doi: 10.1186/s12890-022-01951-x.
5
Predictive value of mRNA expression and dynamic changes from immune related biomarkers in liquid biopsies before and after start of pembrolizumab in stage IV non-small cell lung cancer (NSCLC).
Transl Lung Cancer Res. 2021 Nov;10(11):4106-4119. doi: 10.21037/tlcr-21-587.
6
First-Line Immunotherapy for Non-Small-Cell Lung Cancer.
J Clin Oncol. 2022 Feb 20;40(6):586-597. doi: 10.1200/JCO.21.01497. Epub 2022 Jan 5.
7
Deep Sequencing of T-Cell Receptors for Monitoring Peripheral CD8 T Cells in Chinese Advanced Non-Small-Cell Lung Cancer Patients Treated With the Anti-PD-L1 Antibody.
Front Mol Biosci. 2021 Jul 9;8:679130. doi: 10.3389/fmolb.2021.679130. eCollection 2021.
8
Dynamic changes in circulating PD-1CD8 T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer.
Eur J Cancer. 2021 Jan;143:113-126. doi: 10.1016/j.ejca.2020.10.028. Epub 2020 Dec 7.
9
Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC).
BMC Cancer. 2020 Dec 3;20(1):1185. doi: 10.1186/s12885-020-07690-8.
10
Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer.
Front Immunol. 2020 Feb 7;11:125. doi: 10.3389/fimmu.2020.00125. eCollection 2020.
Zotero 插件